Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years — India, 2014 and updates on immunization

Indian Pediatrics

Volumn 51, Issue 10, 2014, Pages 785-800

  Vashishtha, Vipin M ^a,b   Choudhury, Panna ^a   Kalra, Ajay ^a   Bose, Anuradha ^a   Thacker, Naveen ^a   Yewale, Vijay N ^a   Bansal, C P ^a   Mehta, Pravin J ^a  

^a Indian Academy of Pediatrics   (India)

^b Mangla Hospital and Research Center   (India)

Author keywords

Child; Guidelines; Immunity; MMR Vaccine; Vaccination

Indexed keywords

HEPATITIS A VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH CARE; HEPATITIS A; HUMAN; IMMUNIZATION; INDIA; INDIAN; MEASLES; MEASLES VACCINATION; PEDIATRICIAN; PERTUSSIS; PRE-EXPOSURE PROPHYLAXIS; TYPHOID FEVER; FEMALE; INFANT; MALE; PRACTICE GUIDELINE; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; VACCINES;

EID: 84920939181     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-014-0504-y     Document Type: Article

References (44)

1. Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization and IAP immunization timetable 2012. Indian Pediatr. 2012;49:549–64.
2. Vashishtha VM, Choudhury P, Bansal CP, Yewale VN, Agarwal R. editors. IAP Guidebook on Immunization 2013–2014. National Publication House, Indian Academy of Pediatrics, Gwalior, 2014.
3. Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. IAP perspectives on measles and rubella elimination strategies. Indian Pediatr. 2014;51:719–22.
4. Schoub BD, Johnson S, McAnerney JM, Wagstaff LA, Matsie W, Reinach SG, et al. Measles, mumps, and rubella immunization at nine months in a developing country. Pediatr Infect Dis J. 1990;9:263–7.
5. Singh R, John TJ, Cherian T, Raghupathy P. Immune response to measles, mumps and rubella vaccine at 9, 12 & 15 months of age. Indian J Med Res. 1994;100:155–9.
6. Forleo-Neto E, Carvalho ES, Fuentes IC, Precivale MS, Forleo LH, Farhat CK. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months. Vaccine. 1997;15:1898–901.
7. Yadav S, Thukral R, Chakarvarti A. Comparative evaluation of measles, mumps and rubella vaccine at 9 & 15 months of age. Indian J Med Res. 2003;118:183–6.
8. Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007;35:326–33.
9. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP), Vashishtha VM, Kalra A, Bose A, Choudhury P, Yewale VN, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization. Indian Pediatr. 2013;50:1095–108.
10. Bhave S, Bavdekar A, Madan Z, Jha R, Bhure S, Chaudhari J, et al. Evaluation of immunogenicity and tolerability of a live attenuated hepatitis A vaccine in Indian children. Indian Pediatr. 2006;43:983–7.
11. Faridi MM, Shah N, Ghosh TK, Sankaranarayanan VS, Arankalle V, Aggarwal A, et al. Immunogenicity and safety of live attenuated hepatitis A vaccine: A multicentric study. Indian Pediatr. 2009;46:29–34.
12. World Health Organization. WHO position paper on hepatitis A vaccines — June 2012. Wkly Epidemiol Rec. 2012;87:261–76.
13. Ali SA, Kazi M, Cortese M, Fleming J, Parashar U, Jiang B, et al. Impact of Different Dosing Schedules on the Immunogenicity of the Human Rotavirus Vaccine in Children in Pakistan — a Randomized Controlled Trial (Abstract). Proceedings of the Vaccine for Enteric Disease. 2013 Nov 6–8; Bangkok, Thailand.
14. Armah G, Lewis K, Cortess M, Parashar U, Ansah A, Gazley L, et al. Immunogenicity of the Human Rotavirus Vaccine Given on Alternative Dosing Schedules in Rural Ghana. Proceedings of the Vaccine for Enteric Disease. 2013 Nov 6–8; Bangkok, Thailand.
15. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: A randomized, double blind, placebo-controlled trial. J Infect Dis. 2009;200:421–9.
16. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: A randomised, double-blind, placebo-controlled trial. Lancet. 2014 Mar 11 [E-pub ahead of print].
17. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis. 2007;11:29–35.
18. World Health organization. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85:309–20.
19. Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomized observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014;14:119–29.
20. World Health Organization. Summary of the SAGE April 2014 Meeting. Available from: http://www.who.int/immunization/sage/meetings/2014/april/report_summary_april_2014/en/. Accessed June 15, 2014.
21. World health Organization. Evidence Based Recommendations on Human Papilloma Virus (HPV) Vaccines Schedules. Background paper for SAGE discussions, March 11, 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf?ua=1. Accessed June 15, 2014.
22. rd March 2014 (unpublished).
23. European Medicines Agencies, Committee for Medicinal Products for Human Use (CHMP), Assessment report-Cervarix, EMA/789820/2013, 21 November 2013. Available from: htpp://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Assessement Report-Variation/human/000721/WC500160885.pdf. Accessed June 30, 2014.
24. Sankaranarayanan R. Two vs three doses HPV vaccine schedule: low- and middle-income countries, in Eurogin 2013 International Multidisciplinary Congress. 2013: Florence, Italy.
25. Sankaranarayanan R. Trial of two versus three doses of Human Papillomavirus (HPV) vaccine in India. 2013 [cited 2013 Nov 15]; Available from: http://clinicaltrials.gov/show/NCT00923702. Accessed July 4, 2014.
26. Sankaranarayanan R, Evaluation of fewer than three doses of HPV vaccination in India, in WHO Consultation Meeting. 2013: WHO, Geneva.
27. Vashishtha VM, Bansal CP, Gupta SG. Pertussis vaccines: Position paper of Indian Academy of Pediatrics (IAP). Indian Pediatr. 2013; 50:1001–9.
28. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 1992; 120:184–9.
29. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011; 29:4881–90.
30. Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992;121:187–94.
31. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: Recommendations for immunization with recently and previously licensed vaccines. Pediatrics. 1993; 92:480–8.
32. World Health Organization, WHO Technical Report Series No 941, 2007. Annex 6 Recommendations for whole-cell pertussis vaccine. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/whole_cell_pertussis/Annex%206%20whole%20cell%20pertussis.pdf. Accessed July 7, 2014.
33. World Health Organization. Vaccines and biologicals: Recommendations from the Strategic Advisory Group of Experts. Wkly Epidemiol Rec. 2002; 37:306.
34. Sharma H, Yadav S, Lalwani S, Gupta V, Kapre S, Jadhav S, et al. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants. Vaccine. 2011; 29:2359–64.
35. Rao R, Dhingra MS, Bavdekar S, Behera N, Daga SR, Dutta AK, et al. A comparison of immunogenicity and safety of indigenously developed liquid (DTwPHB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (liq) and TritanrixHB + Hiberix (lyo) in Indian infants administered according to the EPI schedule. Hum Vaccin. 2009;5:425–9.
36. Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, et al. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in Indian infants. Hum Vaccin Immunother. 2013;9:1903–9.
37. Phase III Clinical Trial Report of BBIL’s pentavalent vaccine (DTwP-HepB-Hib) Comvac-5, Protocol No.BBIL/010/016.
38. Phase III Clinical Trial Report of Panacea Biotech’s pentavalent vaccine (DTwP-HepB-Hib) Easyfive vaccine.
39. Package Insert (PI) of Easyfive-TT vaccine. Available from: http://www.who.int/immunization_standards/vaccine_quality/pq_269_dtp_hepb_hib_1dose_panacea_insert.pdf. Accessed July 7, 2014.
40. Package Insert (PI) of ComBEfive. Available from: http://www.who.int/immunization_standards/vaccine_quality/pq_253_254_DTP_HepB_Hib_liquid_BiolE_PI.pdf. Accessed July 7, 2014.
41. Asturias EJ, Contreras-Roldan IL, Ram M, Garcia-Melgar AJ, Morales-Oquendo V, Hartman K, et al. Postauthorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31:5909–14.
42. World Health Organization. WHO prequalified vaccines. Available from: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/. Accessed July 12, 2014.
43. Schmid DA, Macura-Biegun A, Rauscher M. Development and introduction of a ready-to-use pediatric pentavalent vaccine to meet and sustain the needs of developing countries–Quinvaxem®: the first 5 years. Vaccine. 2012;30:6241–48.
44. World Health Organization. A System for the Prequalification of Vaccines for UN supply. Available from: http://www.who.int/immunization_standards/vaccine_quality/pq_system/en/. Accessed July 12, 2014.